Aktis Oncology’s (NASDAQ:AKTS) Lock-Up Period Will End on July 8th

Aktis Oncology’s (NASDAQ:AKTS) lock-up period will end on Wednesday, July 8th. Aktis Oncology had issued 17,650,000 shares in its initial public offering on January 9th. The total size of the offering was $317,700,000 based on an initial share price of $18.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the end of the lock-up period.

Wall Street Analysts Forecast Growth

AKTS has been the subject of a number of analyst reports. Weiss Ratings upgraded shares of Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. William Blair started coverage on Aktis Oncology in a research note on Wednesday, April 29th. They issued an “outperform” rating on the stock. Raymond James Financial began coverage on Aktis Oncology in a research report on Monday, June 15th. They set a “strong-buy” rating and a $40.00 price objective for the company. Finally, HC Wainwright increased their price objective on Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $34.00.

Aktis Oncology Stock Up 7.5%

Shares of Aktis Oncology stock opened at $32.36 on Wednesday. The firm has a fifty day moving average of $21.37. Aktis Oncology has a 12-month low of $14.72 and a 12-month high of $34.19.

Aktis Oncology (NASDAQ:AKTS) last announced its quarterly earnings results on Monday, March 30th. The technology company reported ($18.17) EPS for the quarter. The company had revenue of $1.87 million for the quarter. As a group, research analysts expect that Aktis Oncology will post -1.62 earnings per share for the current year.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.